ema

News

Dyvyzat box, bottle, and oral delivery mechanism.

Italfarmaco closes on EU okay for Duchenne drug

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

Digital

Leveraging data, digitalisation, and artificial intelligence...

In an era marked by rapid technological advancements and evolving healthcare needs, the European Medicines Agencies Network Strategy 2028 stands as a key

News

Surgeon with surgical gloves on holding a brain scan

Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla

The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.

News

EMA panel endorses AI for MASH clinical trials

PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.

News

EMA abandons X in favour of rival Bluesky

The EMA has abandoned X for Bluesky, saying Elon Musk's social media platform "no longer suits our communication needs."

News

In shock move, EU panel rejects Alzheimer's drug Leqembi

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green lig

Italfarmaco closes on EU okay for Duchenne drug

Leveraging data, digitalisation, and artificial intelligence...

Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla

EMA panel endorses AI for MASH clinical trials

EMA abandons X in favour of rival Bluesky

In shock move, EU panel rejects Alzheimer's drug Leqembi

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

ema

Editor's Picks